IL2 and systemic lupus erythematosus: In the Hopkins Lupus Cohort, if lupus nephritis occurs in the first year, the risk of end stage kidney disease was 20% in 20 years.[1] The current treatment of lupus nephritis is inadequate, with only about up to 40% complete renal response at one year, even with the addition of recently approved therapies such as belimumab[2] and voclosporin.[3] Many of the pivotal randomized clinical trials, including of mycophenolate mofetil[4] of tacrolimus[5,6] and of newer therapies such as low dose interleukin-2 (IL-2)[7] have been done in East Asians.